Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Effectiveness of Virtual Reality Training in Amblyopia

NCT: NCT05732467 · COMPLETED

NCT IDNCT05732467
StatusCOMPLETED
Start Date2022-11-14
Completion2024-11-08
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine (OTHER)
First posted
Last updated

Brief Summary

The goal of this clinical trial is to evaluate the efficacy and safety of visual function training software (model: SJ-JRS2021) in the treatment of mild to moderate amblyopia in children. The main questions it aims to answer are: * Whether virtual reality training is more effective than occlusion therapy * Safety of virtual reality training in amblyopia treatment If participants have refractive problems, correct the refraction first and wear corrective glasses. The experimental group will be treated using visual function training therapy software (model: SJ-JRS2021). The control group will be treated with occlusion therapy covering the contralateral eye for 2 hours a day. Researchers will compare experimental group with control group to see if the experimental group has better corrected vision recovery.

Frequently Asked Questions

What is Effectiveness of Virtual Reality Training in Amblyopia?

Effectiveness of Virtual Reality Training in Amblyopia is a clinical trial registered under NCT05732467. Current status: COMPLETED.

What is the status of NCT05732467?

The current status of NCT05732467 (Effectiveness of Virtual Reality Training in Amblyopia) is: COMPLETED.

When did Effectiveness of Virtual Reality Training in Amblyopia start?

Effectiveness of Virtual Reality Training in Amblyopia started on 2022-11-14.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.